De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Swedencare Toekomstige groei

Future criteriumcontroles 4/6

Swedencare zal naar verwachting groeien in winst en omzet met respectievelijk 56.1% en 11.3% per jaar. De winst per aandeel zal naar verwachting groeien met 56.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 4.4% zijn.

Belangrijke informatie

56.1%

Groei van de winst

56.1%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	65.1%
Inkomstengroei	11.3%
Toekomstig rendement op eigen vermogen	4.4%
Dekking van analisten	Low
Laatst bijgewerkt	30 Jul 2024

Recente toekomstige groei-updates

Recent updates

Analysts Just Published A Bright New Outlook For Swedencare AB (publ)'s (STO:SECARE)

Feb 16

Do Swedencare's (STO:SECARE) Earnings Warrant Your Attention?

Dec 28

A Look At The Fair Value Of Swedencare AB (publ) (STO:SECARE)

Dec 06

Swedencare (STO:SECARE) Has A Rock Solid Balance Sheet

Oct 24

With EPS Growth And More, Swedencare (STO:SECARE) Is Interesting

Sep 12

Calculating The Fair Value Of Swedencare AB (publ) (STO:SECARE)

Aug 19

Broker Revenue Forecasts For Swedencare AB (publ) (STO:SECARE) Are Surging Higher

Jul 28

Industry Analysts Just Made A Substantial Upgrade To Their Swedencare AB (publ) (STO:SECARE) Revenue Forecasts

Jul 01

Swedencare (STO:SECARE) Has A Rock Solid Balance Sheet

Jun 29

Winst- en omzetgroeiprognoses

OM:SECARE - Toekomstschattingen van analisten en financiële gegevens uit het verleden (SEK Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	3,310	425	712	N/A	1
12/31/2025	2,972	295	594	N/A	2
12/31/2024	2,611	173	446	N/A	1
6/30/2024	2,472	76	351	414	N/A
3/31/2024	2,414	72	381	415	N/A
12/31/2023	2,338	59	408	444	N/A
9/30/2023	2,199	87	410	444	N/A
6/30/2023	2,085	53	332	376	N/A
3/31/2023	1,987	97	257	314	N/A
12/31/2022	1,843	95	193	260	N/A
9/30/2022	1,600	98	96	170	N/A
6/30/2022	1,335	105	69	135	N/A
3/31/2022	1,019	60	114	161	N/A
12/31/2021	773	55	98	126	N/A
9/30/2021	618	40	90	106	N/A
6/30/2021	465	44	74	79	N/A
3/31/2021	337	34	45	48	N/A
12/31/2020	240	33	36	37	N/A
9/30/2020	174	34	26	29	N/A
6/30/2020	136	28	28	31	N/A
3/31/2020	134	30	20	24	N/A
12/31/2019	127	30	28	33	N/A
9/30/2019	121	30	27	32	N/A
6/30/2019	113	28	23	30	N/A
3/31/2019	108	27	21	28	N/A
12/31/2018	99	23	13	22	N/A
9/30/2018	94	23	16	21	N/A
6/30/2018	92	20	12	15	N/A
3/31/2018	85	17	N/A	14	N/A
12/31/2017	86	17	N/A	13	N/A
9/30/2017	78	12	N/A	4	N/A
6/30/2017	70	11	N/A	4	N/A
3/31/2017	63	12	N/A	4	N/A
12/31/2016	54	10	N/A	2	N/A
9/30/2016	43	9	N/A	8	N/A
6/30/2016	37	8	N/A	9	N/A
3/31/2016	34	8	N/A	5	N/A
12/31/2015	27	7	N/A	4	N/A
12/31/2014	24	4	N/A	4	N/A
12/31/2013	18	0	N/A	N/A	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei SECARE ( 56.1% per jaar) ligt boven de spaarquote ( 1.1% ).

Winst versus markt: De winst van SECARE ( 56.1% per jaar) zal naar verwachting sneller groeien dan de Swedish markt ( 15.2% per jaar).

Hoge groeiwinsten: De winst van SECARE zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van SECARE ( 11.3% per jaar) zal naar verwachting sneller groeien dan de markt Swedish ( 1.4% per jaar).

Hoge groei-inkomsten: De omzet van SECARE ( 11.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen SECARE zal naar verwachting over 3 jaar laag zijn ( 4.4 %).

Swedencare Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 22%

Price target increased by 8.7% to kr50.00

Price target decreased by 7.1% to kr46.00

Price target increased by 10% to kr49.50

Consensus EPS estimates fall by 31%, revenue upgraded

Price target decreased by 12% to kr42.00

Recent updates

Swedencare AB (publ) to Report Q2, 2025 Results on Jul 24, 2025

Chief Executive Officer recently bought kr874k worth of stock

Consensus EPS estimates fall by 22%

Chief Executive Officer recently bought kr941k worth of stock

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Swedencare AB (publ) to Report Q4, 2024 Results on Feb 13, 2025

Upcoming dividend of kr0.23 per share

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Swedencare AB (Publ) Announces Nomination Committee Appointments

Price target increased by 8.7% to kr50.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Swedencare AB (publ), Annual General Meeting, Apr 25, 2024

New minor risk - Share price stability

Price target decreased by 7.1% to kr46.00

Price target increased by 10% to kr49.50

Consensus EPS estimates fall by 31%, revenue upgraded

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: kr0.10 (vs kr0.49 in 2Q 2022)

Investor sentiment improves as stock rises 15%

Chief Executive Officer recently bought kr472k worth of stock

Symrise AG (XTRA:SY1) announces a mandatory public offer to acquire remaining 70% stake in Swedencare AB (publ) (OM:SECARE) for SEK 4.2 billion

Symrise AG (XTRA:SY1) announces a mandatory public offer to acquire remaining 70% stake in Swedencare AB (publ) (OM:SECARE) for SEK 4.2 billion

Investor sentiment improves as stock rises 15%

Less than half of directors are independent

Price target decreased by 12% to kr42.00

First quarter 2023 earnings: EPS misses analyst expectations

Does Swedencare (STO:SECARE) Deserve A Spot On Your Watchlist?

Investor sentiment improves as stock rises 22%

Upcoming dividend of kr0.22 per share at 0.8% yield

Chief Executive Officer recently bought kr241k worth of stock

Chief Executive Officer recently bought kr241k worth of stock

Consensus EPS estimates fall by 27%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased by 14% to kr47.25

Swedencare AB (publ) to Report Fiscal Year 2022 Final Results on Apr 06, 2023

Swedencare AB (publ) to Report First Half, 2023 Results on Jul 27, 2023

Swedencare AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023

Investor sentiment improved over the past week

Chief Executive Officer recently bought kr315k worth of stock

Chief Executive Officer recently bought kr328k worth of stock

Swedencare (STO:SECARE) Seems To Use Debt Quite Sensibly

Swedencare AB (publ), Annual General Meeting, Apr 28, 2023

Investor sentiment deteriorated over the past week

Here's Why We Think Swedencare (STO:SECARE) Might Deserve Your Attention Today

Price target decreased to kr75.00

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

With EPS Growth And More, Swedencare (STO:SECARE) Makes An Interesting Case

Consensus forecasts updated

Price target decreased to kr120

Second quarter 2022 earnings released: EPS: kr0.49 (vs kr0.31 in 2Q 2021)

Swedencare (STO:SECARE) Has A Pretty Healthy Balance Sheet

High number of new directors

Chief Executive Officer recently bought kr162k worth of stock

Consensus forecasts updated

Price target decreased to kr165

Less than half of directors are independent

Upcoming dividend of kr0.20 per share

Should You Be Adding Swedencare (STO:SECARE) To Your Watchlist Today?

Swedencare AB (publ) Proposes Dividend, Payable on 5 May 2022

Price target decreased to kr165

Swedencare AB (Publ) Proposes Dividend for 2021

Analysts Just Published A Bright New Outlook For Swedencare AB (publ)'s (STO:SECARE)

Now 23% undervalued after recent price drop

Swedencare AB (publ) (OM:SECARE) agreed to acquire The Garmon Corporation for approximately $470 million.

Do Swedencare's (STO:SECARE) Earnings Warrant Your Attention?